Evolent Health Inc (NYSE:EVH) Director Cheryl Scott sold 1,600 shares of the business’s stock in a transaction that occurred on Monday, June 11th. The shares were sold at an average price of $22.63, for a total transaction of $36,208.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.

Shares of EVH opened at $23.25 on Wednesday. Evolent Health Inc has a fifty-two week low of $10.30 and a fifty-two week high of $27.25. The company has a market cap of $1.77 billion, a P/E ratio of -33.21 and a beta of 1.14. The company has a current ratio of 2.88, a quick ratio of 2.88 and a debt-to-equity ratio of 0.12.

Evolent Health (NYSE:EVH) last announced its earnings results on Wednesday, May 9th. The technology company reported $0.02 earnings per share for the quarter, topping the consensus estimate of ($0.04) by $0.06. Evolent Health had a negative net margin of 12.11% and a negative return on equity of 2.16%. The firm had revenue of $139.70 million for the quarter, compared to the consensus estimate of $140.89 million. During the same period in the prior year, the firm earned ($0.14) EPS. The firm’s revenue for the quarter was up 31.5% on a year-over-year basis. research analysts forecast that Evolent Health Inc will post -0.33 earnings per share for the current fiscal year.

Institutional investors and hedge funds have recently made changes to their positions in the stock. Quantbot Technologies LP increased its stake in Evolent Health by 111.4% during the 1st quarter. Quantbot Technologies LP now owns 10,815 shares of the technology company’s stock worth $154,000 after buying an additional 5,698 shares during the period. Jane Street Group LLC purchased a new stake in Evolent Health during the 4th quarter worth approximately $144,000. LPL Financial LLC purchased a new stake in Evolent Health during the 1st quarter worth approximately $184,000. Xact Kapitalforvaltning AB purchased a new stake in Evolent Health during the 1st quarter worth approximately $190,000. Finally, Virtu Financial LLC purchased a new stake in Evolent Health during the 4th quarter worth approximately $172,000.

A number of equities research analysts have recently issued reports on EVH shares. ValuEngine downgraded shares of Evolent Health from a “sell” rating to a “strong sell” rating in a research note on Monday, April 2nd. Canaccord Genuity reduced their price target on shares of Evolent Health from $27.00 to $24.00 and set a “buy” rating on the stock in a research note on Wednesday, February 28th. Zacks Investment Research downgraded shares of Evolent Health from a “hold” rating to a “sell” rating in a research note on Thursday, March 8th. SunTrust Banks boosted their price target on shares of Evolent Health and gave the company a “buy” rating in a research note on Thursday, June 7th. Finally, Wells Fargo & Co reduced their price target on shares of Evolent Health from $27.00 to $20.00 and set an “outperform” rating on the stock in a research note on Wednesday, February 28th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and thirteen have assigned a buy rating to the company. The stock has a consensus rating of “Buy” and an average target price of $25.64.

Evolent Health Company Profile

Evolent Health, Inc, through its subsidiary, Evolent Health LLC, provides health care delivery and payment solutions in the United States. The company operates as a managed services firm that supports health systems and physician organizations in migration toward value-based care and population health management.

Insider Buying and Selling by Quarter for Evolent Health (NYSE:EVH)

Receive News & Ratings for Evolent Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evolent Health and related companies with MarketBeat.com's FREE daily email newsletter.